Topics

Hemispherx BioPharma reports positive results on ovarian cancer treatment

04:40 EDT 1 May 2019 | Proactive Investors

Hemispherx BioPharma (NYSE American:HEB) CEO Thomas Equels tells Proactive Investors that the biopharma has made significant progress in the study of its flagship drug Ampligen in treating ovarian cancer.

Equels is presenting at the Planet MicroCap Showcase today, in Las Vegas. A live webcast of the presentation can be viewed here:

https://www.webcaster4.com/Webcast/Page/2059/30408

Original Article: Hemispherx BioPharma reports positive results on ovarian cancer treatment

NEXT ARTICLE

More From BioPortfolio on "Hemispherx BioPharma reports positive results on ovarian cancer treatment"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...